Roivant Sciences Ltd.

Roivant Sciences Ltd. is a U.S.-based biopharmaceutical company organized around a portfolio of development-stage medicines and technology-enabled subsidiaries, or "Vants." Its business spans drug discovery, clinical development, and eventual commercialization across autoimmune, inflammatory, and pulmonary disease programs, while also incubating complementary health technology and discovery-stage ventures.

−6 195,2 %

−3 629,2 %

−71,6 %

18.37

18.37

— Roivant Sciences Ltd.
%
Clinical-stage therapeutics70% Drug candidates in development for autoimmune, inflammatory, and pulmonary diseases.
Licensing and collaboration revenue20% Revenue earned from license agreements and related partnering arrangements.
Subscription and service-based technology revenue10% Fees from technology-related subscriptions and services.

Roivant's direct counterparties are primarily pharmaceutical and biotechnology partners, licensees, and collaborators...

  • Pharmaceutical and biotech partnersprimary

    License and collaboration counterparties that support development, commercialization, or asset monetization.

  • Patients with autoimmune and inflammatory diseasesprimary

    End users of therapies such as brepocitinib, IMVT-1402, and batoclimab if approved.

  • Patients with pulmonary vascular diseasesecondary

    Potential end users of mosliciguat in pulmonary hypertension associated with interstitial lung disease.

  • Technology and service customerssecondary

    Subscribers or users of technology-enabled services that generate recurring or service-based revenue.

Roivant is headquartered in the United States and operates as a global biopharmaceutical platform through subsidiaries...

  • •Headquartered in the United States
  • •Clinical and regulatory activity spans U.S. and international markets
  • •FDA approval is central for commercialization in the U.S.
  • •European and U.K. exclusivity rules affect future product economics
  • •Subsidiary structure allows programs to be developed across regions

Roivant's strategy is to build and advance a diversified pipeline through small, focused subsidiaries that can move...

01
Advance core clinical programsmedium-term

Late-stage assets are the main source of future value creation and potential commercialization.

02
Scale the Vant operating modelmedium-term

Centralized support and subsidiary autonomy are intended to improve development efficiency.

03
Optimize capital allocationshort-term

Cash can be used for development, acquisitions, or shareholder returns depending on opportunity set.

Roivant faces the standard risks of biopharmaceutical development: clinical failure, regulatory delay, and uncertainty...

high

Clinical development failure

Pipeline value depends on positive trial outcomes for multiple product candidates.

Scope
Brepocitinib, IMVT-1402, batoclimab, mosliciguat
Materiality
high
high

Regulatory approval risk

Medicines cannot be marketed without FDA or other authority approval.

Scope
All product candidates
Materiality
high
medium

Commercialization execution risk

Launching approved products requires sales, marketing, reimbursement, and distribution capabilities.

Scope
Late-stage Vants
Materiality
high
medium

Capital allocation and funding risk

Development programs and acquisitions require substantial capital over time.

Scope
Pipeline expansion and in-licensing
Materiality
high
medium

Intellectual property and exclusivity risk

Future economics depend on patent protection and regulatory exclusivity periods.

Scope
Orphan-drug and product exclusivity
Materiality
medium
License agreement revenue recognition
Can create lumpy quarterly revenue
Subscription and service-based revenue
Affects recurring revenue visibility
Fair value of marketable securities
Can affect other income and liquidity presentation
Discontinued operations and divestiture accounting
Can distort comparability across periods

Immunovant, Inc.

IMVT · Biological Products, (No Diagnostic Substances)

Inhibikase Therapeutics, Inc.

IKT · Biological Products, (No Diagnostic Substances)

PLIANT THERAPEUTICS, INC.

PLRX · Pharmaceutical Preparations

TENAX THERAPEUTICS, INC.

TENX · Pharmaceutical Preparations

Replimune Group, Inc.

REPL · Biological Products, (No Diagnostic Substances)

Monopar Therapeutics

MNPR · Pharmaceutical Preparations

: 29/04/2026